Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.-Reference-Cited by-同舟云学术

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

Published:2018-05-20 Issue:15_suppl Volume:36 Page:9002-9002
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Socinski Mark A.¹,Jotte Robert M.²,Cappuzzo Federico³,Orlandi Francisco Jorquera⁴,Stroyakovskiy Daniil⁵,Nogami Naoyuki⁶,Rodriguez-Abreu Delvys⁷,Moro-Sibilot Denis⁸,Thomas Christian A.⁹,Barlesi Fabrice¹⁰,Finley Gene Grant¹¹,Kelsch Claudia¹²,Lee Anthony¹³,Coleman Shelley¹²,Shen Yijing¹²,Kowanetz Marcin¹²,Lopez-Chavez Ariel¹²,Sandler Alan¹²,Reck Martin¹⁴

Affiliation:

1. Florida Hospital Cancer Institute, Orlando, FL;

2. Rocky Mountain Cancer Centers, Denver, CO;

3. AUSL Romagna, Ravenna, Italy;

4. Instituto Nacional del Torax, Santiago, Chile;

5. Moscow City Oncology Hospital #62, Moscow, Russian Federation;

6. Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan;

7. Hospital Universitavio Insular De Gran Canaria, Las Palmas, Spain;

8. Centre Hospitalier Universitaire de Grenoble, Grenoble, France;

9. New England Cancer Specialists, Scarborough, ME;

10. Hospital Nord Service Oncologie, Marseille, France;

11. Allegheny Health Network Cancer Institute, Pittsburgh, PA;